CA2259460A1 - Recombinant canine adenovirus (cav) containing exogenous dna - Google Patents
Recombinant canine adenovirus (cav) containing exogenous dnaInfo
- Publication number
- CA2259460A1 CA2259460A1 CA002259460A CA2259460A CA2259460A1 CA 2259460 A1 CA2259460 A1 CA 2259460A1 CA 002259460 A CA002259460 A CA 002259460A CA 2259460 A CA2259460 A CA 2259460A CA 2259460 A1 CA2259460 A1 CA 2259460A1
- Authority
- CA
- Canada
- Prior art keywords
- recombinant
- cav
- exogenous dna
- expression products
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701157 Canine mastadenovirus A Species 0.000 title abstract 3
- 108091029865 Exogenous DNA Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102100038909 Caveolin-2 Human genes 0.000 abstract 1
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed and claimed are recombinant adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. More particularly, disclosed and claimed are recombinant canine adenoviruses (CAV) and methods of making them, uses for them, expression products from them, and uses for the expression products, including recombinant CAV2 viruses. Additionally, disclosed and claimed are truncated promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2569241A CA2569241C (en) | 1996-07-03 | 1997-06-30 | Recombinant canine adenovirus (cav) containing exogenous dna |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/675,556 | 1996-07-03 | ||
US08/675,566 US6090393A (en) | 1996-07-03 | 1996-07-03 | Recombinant canine adenoviruses, method for making and uses thereof |
US08/675,566 | 1996-07-03 | ||
US08/675,556 US6156567A (en) | 1996-07-03 | 1996-07-03 | Truncated transcriptionally active cytomegalovirus promoters |
PCT/US1997/011486 WO1998000166A1 (en) | 1996-07-03 | 1997-06-30 | Recombinant canine adenovirus (cav) containing exogenous dna |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2569241A Division CA2569241C (en) | 1996-07-03 | 1997-06-30 | Recombinant canine adenovirus (cav) containing exogenous dna |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2259460A1 true CA2259460A1 (en) | 1998-01-08 |
CA2259460C CA2259460C (en) | 2007-03-13 |
Family
ID=38008080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002259460A Expired - Lifetime CA2259460C (en) | 1996-07-03 | 1997-06-30 | Recombinant canine adenovirus (cav) containing exogenous dna |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2259460C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109715219A (en) * | 2016-09-20 | 2019-05-03 | 勃林格殷格翰动物保健有限公司 | Canine adenovirus vector |
-
1997
- 1997-06-30 CA CA002259460A patent/CA2259460C/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109715219A (en) * | 2016-09-20 | 2019-05-03 | 勃林格殷格翰动物保健有限公司 | Canine adenovirus vector |
CN109715219B (en) * | 2016-09-20 | 2024-03-01 | 勃林格殷格翰动物保健有限公司 | Canine adenovirus vector |
Also Published As
Publication number | Publication date |
---|---|
CA2259460C (en) | 2007-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0979101A4 (en) | Recombinant canine adenovirus (cav) containing exogenous dna | |
CA2189882A1 (en) | Papillomavirus vaccines | |
PL339735A1 (en) | Pappiloma virus capsomer vaccine compositions and methods of applying them | |
EP1616954A9 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
AU681705B2 (en) | Endosomolytically active particles | |
CA2193210A1 (en) | Method of inducing an immune response with a live venezuelan equine encephalitis virus expressing a heterologous immunogen | |
AU688321B2 (en) | Biocompatible implant for the expression and secretion in vivo of a therapeutic compound | |
AU2774389A (en) | Recombinant vaccinia virus mva | |
MX9709549A (en) | Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses. | |
WO1995006743A3 (en) | Methods and compositions for the large scale production of recombinant adeno-associated virus | |
CA2303477A1 (en) | Chimaeric adenoviruses | |
EP1923467A3 (en) | Adenovirus vectors for gene therapy | |
DK0835133T3 (en) | Recombinant smallpox virus rabies and combination preparations and their uses | |
WO1998027204A3 (en) | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors | |
GEP20032902B (en) | Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV | |
EP0278940A3 (en) | Hepatitis b virus surface antigens and hybrid antigens containing them | |
WO1998037095A3 (en) | Recombinant pox virus for immunization against muc1 tumor-associated antigen | |
CA2074502A1 (en) | Vaccines | |
WO1996021035A3 (en) | Retroviral delivery of full length factor VIII | |
EP0370458A3 (en) | Synthetic DNA derived recombinant HIV-1 antigens | |
CA2250078A1 (en) | Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
AU4723596A (en) | Method for preparing a recombinant adenovirus genome | |
EP1471146A3 (en) | A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors | |
WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
CA2448908A1 (en) | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20170630 |